THIS SHARE WILL BE WORTH 3.00 IN 2009

Sell off on Wall St Friday will point the way - another fall

With 98% of the FTSE down today, I also expected Protherics to open down, but it did not and at 0845 it's still up. OK only .25p but strange as there appears very little interest in the share.

Hi Greekman,

No interest whatsoever and no follow up with the spike on Friday.

Need more news.

Yes, I was expecting PTI to fall, too, but am pleased to note it's just about holding steady.

I still reckon that they must be negotiating some other deals. If an Akzo Nobel company (Nobilon - as in the RNS of 26Sept) is happy to pay for PTI's technology, then I'm sure there are other significant pharmacos keen to work with them.

I'm going to remain patient an hold.

Toya,there you go answered your own question on PET thread!

"I'm going to remain patient an hold."

Hi Lex1000 - you tracked me down! Yes, and I shall continue to hold. It's ticked up a bit today, to 50-51p, so it's starting to move in the right direction.

AXA Holdings.

AXA must feel confident, as 12% is a big slice of a company in monetary terms even one with a market cap the size of Protherics.
I'm always happy for a single holder, be it a PI or investment group to own such a percentage of a companies shares. It's when that percentage reaches toward 30% that I become worried as when they hold such a market share they can become a bit too relative to sp movement should they suddenly decide to reduce. I saw this recently with another share I hold.
But as said quite happy with AXA holding 12%.
Just hope they are calling it right.

Morning Greekman - price up nicely to 52.25-53.50. Off to a good start at least.

Hi,

Won't get much time to watch the markets today but it is looking progressively better this week, especially with most of their peers taking a knock of late.

I won't be able to keep my eye on it all day either, but I'm confident that the price will stay up there even while my back is turned.

It may do unless the chartist take note, due to the RSI indicator viewing the SP as approaching overvalued.
Myself... I don't take much notice of chart indicators when it comes to companies such as Protherics, whose fortunes can half/double overnight on one bad/good bit of news.

Quite agree.

This week could be interesting I feel PTI is about to wake a few people up!!!

There must be some news in the pipeline.

I think it's anyones guess at the moment re the markets.
What with the cost of oil, sub-prime still bubbling, the dollar situation, Pakistan, Iraq, Turkey/Iran the UK debt, global warming, floods, road congestion, household bills, my bank statement, wifes Xmas wants (ba humbug), ad infinitum.
Think I will hibernate till it's all over.

Depends on what you mean by "all over". Suggest you buy a sandwich board and patrol outside the Stock Exchange!

Hi Halifax,

Just think what my views would be if I was a pessimist and not an optimist.
But seriously, I think Protherics are in a very good position re their drug portfolio, to greatly increase the sp either on a world stock market pick-up or/and on a positive significant news release re one of their drugs in trial.
In Potherics, I think we are as safe (and safer than many companies) as anywhere at the present.

With the build up of Axa and the results out tomorrow, looking forward to 0700 hrs.
With blood all over the markets, PTI had a very good day.

The only conclusion I can come to re the SP is the loss that Protherics is making.
Loss is the only negative in the results, although if you look at the loss along with the other figures, it is only the result of the increase in R&D.
Revenue growth is up 31%.
Gross profit up 32%.
Margins about the same at 55.4% (all down to an excellent management team).
Loss before tax up 6.1 mil. (because of the R&D increase).
Net cash up 14.4 mil.
CASH....46.9 mil (so if the same loss bt continued, it could be carried for several years).

Most will look at these figures as indicating a company well on track for profit within the next 12 months with a very prosperous few years ahead.

Because Protherics are a small, market value drug/bio company compared to those bigger boys in the sector who are year by year well into profit making in huge numbers, the share seams to stall whenever the word LOSS is mentioned, or/and the word delay.

Protherics must have the best (for it's size) drug portfolio in the sector, but as we have seen many times, as soon as there is a delay for whatever reason of a drugs progress, the sellers pile in.

I expect delays, disappointments along the way. Thats the way of the beast.
If half of the drug pipeline make it to full production, I will be happy.
And half is well above all drugs from initial conception to full use acceptance.

My belief is that many holders in the past, with probably some still holding just don't understand the ways of such companies products.

I for one will continue to hold for what I believe the future has in store for Protherics.

If only more PI's would look at the fundamentals and compare Protherics with their competitors, of a similar size, and forget at this stage the EPS.

OK if you want Protherics to make you money now then forget it (allowing for the possible upgrade in market sentiment of course). But if you want to be in on the big party, don't wait till the entry fee costs go up.

All IMHO of course.

Nice little BUY recommendation from The Independent. Nothing that we don't know from yesterday but the more interest the better.

Protherics, one of the UK's most established biopharmaceutical companies, is gearing up for a big 2008. It is second-nature for life sciences companies to point to jam tomorrow, but with six products entering phase II trials over the next six months, Protherics is able to boast that it has a larger development pipeline than any other UK biotech.

Yesterday's interim results illustrate why Protherics is well-regarded. The company's underlying revenue growth was an impressive 41 per cent at constant currency rates, while its pre-tax loss of 6m was much better than had been expected.

Perhaps more significantly, Protherics reported a cash pile of 47m, giving it the firepower to continue to develop a number of potential blockbuster drugs under its wing.

Be nice to see if there is further institutional interest over next 6 to 12 months.

Biotech recruiter Accord Scientific has partnered with international biopharmaceutical company Protherics Inc. to build Protherics' clinical regulatory and senior staff.

Accord was selected to support Protherics after Protherics' acquisition of Utah-based MacroMed Inc., a private drug development and manufacturing company and two in-licensing agreements the company has signed with Glenveigh Pharmaceuticals and Advancell of Barcelona. The three transactions have roughly doubled the size of Protherics' U.S. Operations.

Proves PTI's are treating the USA projects very seriously.